A US Multi-center Observational Study on the Long-Term Safety and Effectiveness of SKYTROFA Lonapegsomatropin in Patients with Growth Hormone Deficiency

What this Trial Is About

This research aims to gather long-term evidence on the safety and effectiveness of SKYTROFA lonapegsomatropin in patients with growth hormone deficiency who are receiving routine clinical care. The study focuses on understanding how patients respond to this treatment over time without altering their usual medical management. It is a non-interventional observational study conducted across multiple centers in the USA. Patients will continue their regular treatment with SKYTROFA as managed by their healthcare providers, with no additional visits, examinations, or tests required beyond standard clinical care. The study will collect data from clinical outcome assessments COAs to evaluate treatment results and safety over a period of five years. No experimental interventions or placebos are involved. Participants will be monitored through their routine clinical visits, with researchers reviewing their health status and treatment effectiveness using standard assessments. The primary outcomes include measuring safety and treatment effectiveness over five years, along with evaluating clinical outcomes through COAs. This approach allows for natural observation of patient experiences without extra procedures or disruptions to their care.

A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA